Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Cancer Prev Res (Phila). 2016 Dec 13;10(2):108–115. doi: 10.1158/1940-6207.CAPR-16-0219

Table 2.

Summary of microsatellite Instability (MSI) and Immunohistochemistry (IHC) results.

MSI Status Number %*
MSI-Low 6 3.0
MSI-Stable 143 71.9
MSI-High 50 25.1

IHC Result

Intact MLH1, MSH2, MSH6, PMS2 146 72.6
Loss of MLH1 & PMS2 46 22.8
 With MLH1 methylation 43 93.5
 Without MLH1 methylation 3 6.5
Loss of MSH2 & MSH6 2 1.0
Loss of MSH6 only 3 1.5
Loss of PMS2 only 3 1.5
*

Percent of tested endometrial cancers (MSI – 199; Immunohistochemistry – 203)